Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Deoxycholic Acid Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Submental Study (Sequential Treatment Approach)

NCT03510598
View directory record Official record
Conditions
Body Fat Disorder
Interventions
The ZELTIQ CoolSculpting System, Kybella 20 MG in 2 ML Injection
Device · Drug
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
22 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of Deoxycholic Acid Injections for Removal of Adipose Tissue in the "Bra Strap Fat" Region

NCT04089722
View directory record Official record
Conditions
Brassiere Strap Fat (BSF), Bra Strap Fat (BSF)
Interventions
Deoxycholic Acid
Drug
Lead sponsor
Juva Skin & Laser Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

NCT01904058
View directory record Official record
Conditions
PBC, Primary Biliary Cirrhosis
Interventions
LUM001, Placebo, Ursodeoxycholic Acid
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ATX-101 Abdominoplasty

NCT00835952
View directory record Official record
Conditions
Characteristics of Subcutaneous Fat
Interventions
ATX-101
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
25 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
San Francisco, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2010 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat

NCT03241563
View directory record Official record
Conditions
Fat Reduction
Interventions
Sodium Deoxycholate, Triamcinolone
Drug
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2017 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area

NCT01426373
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
18
States / cities
Beverly Hills, California • La Jolla, California • San Juan Capistrano, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

NCT02159729
View directory record Official record
Conditions
Submental Fat, Healthy
Interventions
Placebo, ATX-101 (1 mg/cm^2), ATX-101 (2 mg/cm^2), ATX-101 (4 mg/cm^2)
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
10
States / cities
Birmingham, Alabama • Beverly Hills, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

NCT02035267
View directory record Official record
Conditions
Moderate to Severe Convexity of Submental Fat, Safety, Efficacy
Interventions
Deoxycholic Acid, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
8
States / cities
Newport Beach, California • San Francisco, California • West Hollywood, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

NCT02163902
View directory record Official record
Conditions
Submental Fat, Healthy
Interventions
ATX-101, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
13
States / cities
San Diego, California • Englewood, Colorado • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis

NCT01088607
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
ursodeoxycholic acid (UDCA)
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
5 Years to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 24, 2026, 4:41 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Lithotripsy for the Treatment of Gallstones

NCT00042549
View directory record Official record
Conditions
Cholelithiasis
Interventions
Extracorporeal Shock Wave Lithotripsy, ursodiol
Device · Drug
Lead sponsor
Medstone International
Industry
Eligibility
18 Years to 90 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
2
States / cities
Houston, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 24, 2026, 4:41 PM EDT
Not yet recruiting Early Phase 1 Interventional

Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy

NCT06884748
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Ursodiol 500 MG
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 24, 2026, 4:41 PM EDT
Enrolling by invitation Phase 1 Interventional

Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)

NCT06300502
View directory record Official record
Conditions
Neurofibromas, Cutaneous, Neurofibromatosis 1
Interventions
Kybella
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)

NCT00706381
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Sincalide, Ursodiol, Fat Meal, Carb meal, Placebo
Drug · Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 24, 2026, 4:41 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Trial of High-dose Urso in Primary Sclerosing Cholangitis

NCT00059202
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Ursodeoxycholic Acid, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas

NCT06132165
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
Deoxycholic Acid, Polidocanol, 1064nm Nd:YAG laser, 755nm Alexandrite Laser
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age

NCT02123134
View directory record Official record
Conditions
Moderate to Severe Convexity of Submental Fat, Safety, Efficacy
Interventions
ATX-101, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
65 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Bradenton, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Kybella With Triamcinolone

NCT03361176
View directory record Official record
Conditions
Adiposity
Interventions
Injectable sodium deoxycholate, Injectable sodium deoxycholate with Triamcinolone acetate
Drug · Combination Product
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
San Diego, California • Hunt Valley, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Deoxycholic Acid Injection for Reduction of Upper Inner Thigh Fat

NCT04054011
View directory record Official record
Conditions
Adiposity
Interventions
Deoxycholic Acid
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas

NCT06120036
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
Kybella, Asclera
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Kybella for the Treatment of Flank Fat (FF)

NCT04841551
View directory record Official record
Conditions
Adiposity
Interventions
Kybella Flanks
Drug
Lead sponsor
Beer, Kenneth R., M.D., PA
Individual
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas

NCT04730583
View directory record Official record
Conditions
Cutaneous Neurofibroma
Interventions
Kybella, 1064nm laser, 755nm Alexandrite Laser
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition

NCT04640571
View directory record Official record
Conditions
Bile Salt Export Pump (BSEP) Transporter, Polysorbate 80
Interventions
pravastatin and chenodeoxycholic acid, after metformin and placebo, valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Sep 24, 2026, 4:41 PM EDT
Completed Phase 4 Interventional

A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products

NCT06783621
View directory record Official record
Conditions
Facial Contouring
Interventions
OnabotulinumtoxinA, JUVÉDERM, CoolSculpting Elite System, SkinMedica Products, KYBELLA
Drug · Device · Other
Lead sponsor
AbbVie
Industry
Eligibility
22 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Redondo Beach, California • Vista, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 24, 2026, 4:41 PM EDT